Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4972 |
Name | myelodysplastic/myeloproliferative neoplasm |
Definition | A myeloid neoplasm that results_in the overproduction of white blood cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:6470 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm myelodysplastic/myeloproliferative neoplasm |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
SETBP1 mutant | N/A | myelodysplastic/myeloproliferative neoplasm | not applicable | detail... |
ASXL1 inact mut | N/A | myelodysplastic/myeloproliferative neoplasm | not applicable | detail... |
CBL mutant | N/A | myelodysplastic/myeloproliferative neoplasm | not applicable | detail... |
ASXL1 wild-type TET2 mut | Azacitidine | myelodysplastic/myeloproliferative neoplasm | sensitive | detail... |
ASXL1 wild-type TET2 mut | Decitabine | myelodysplastic/myeloproliferative neoplasm | sensitive | detail... |
Unknown unknown | Ruxolitinib | myelodysplastic/myeloproliferative neoplasm | not applicable | detail... |
EZH2 mutant | N/A | myelodysplastic/myeloproliferative neoplasm | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00946647 | Phase II | Panobinostat Azacitidine | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | Completed | USA | CAN | 12 |
NCT01164163 | Phase I | Ruxolitinib | INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease | Completed | USA | 0 |
NCT01398462 | Phase I | CWP232291 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Completed | USA | 1 |
NCT01449058 | Phase Ib/II | Alpelisib + Binimetinib | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | 6 |
NCT01746849 | Phase II | Leuprolide Cyclophosphamide Thiotepa Palifermin | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | Recruiting | USA | 0 |
NCT01787487 | Phase II | Azacitidine + Ruxolitinib | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Recruiting | USA | 0 |
NCT01822509 | Phase I | Ipilimumab + Nivolumab | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT01829971 | Phase I | MRX34 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Terminated | USA | 1 |
NCT02089230 | Phase Ib/II | Binimetinib | MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | Completed | USA | 0 |
NCT02143635 | Phase I | HDM201 | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | USA | 7 |
NCT02493530 | Phase I | Ruxolitinib + Umbralisib | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | Active, not recruiting | USA | 0 |
NCT02530476 | Phase Ib/II | Selinexor + Sorafenib | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02564536 | Phase I | Decitabine + Pacritinib | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) | Withdrawn | 0 | |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma | Recruiting | USA | 0 |
NCT02749708 | Phase Ib/II | IRX5183 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT02795520 | Phase Ib/II | OTS167 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | Recruiting | USA | 0 |
NCT02807272 | Phase II | Tipifarnib | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML) | Active, not recruiting | USA | 0 |
NCT02829840 | Phase Ib/II | Azacitidine + Ponatinib | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | Withdrawn | 0 | |
NCT02907359 | Phase III | Cytarabine Guadecitabine | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | Completed | USA | CAN | 12 |
NCT02935361 | Phase Ib/II | Atezolizumab + Guadecitabine | Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed | Recruiting | USA | 0 |
NCT03072043 | Phase Ib/II | APR-246 + Azacitidine | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT03075826 | Phase II | Guadecitabine | A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms | Active, not recruiting | USA | 0 |
NCT03128034 | Phase Ib/II | Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03238248 | Phase II | Azacitidine + MLN4924 | Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors | Recruiting | USA | 0 |
NCT03289910 | Phase II | Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Recruiting | USA | 0 |
NCT03326310 | Phase I | Azacitidine + Selumetinib | Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia | Recruiting | USA | 0 |
NCT03397173 | Phase II | Azacitidine + Vitamin C | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | Active, not recruiting | USA | 0 |
NCT03613532 | Phase I | Busulfan + Fludarabine + Venetoclax | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT03807063 | Phase I | Rimiducid BPX-501 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03886662 | Phase Ib/II | LB-100 | A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) | Recruiting | USA | 0 |
NCT03912064 | Phase I | Ipilimumab | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Recruiting | USA | 0 |
NCT04016116 | Phase II | Pembrolizumab + Ruxolitinib Pembrolizumab | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | Withdrawn | USA | 0 |
NCT04022785 | Phase I | Azacitidine + PLX51107 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04055844 | Phase II | Decitabine + Ruxolitinib | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | Recruiting | USA | 0 |
NCT04103645 | Phase II | TEW 7197 | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | Recruiting | USA | 0 |
NCT04187703 | Phase I | Azacitidine + Decitabine | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies | Recruiting | USA | 0 |
NCT04282187 | Phase II | Decitabine + Fedratinib Decitabine + Ruxolitinib | Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | Recruiting | USA | 0 |